Caisson Interventional Expands Facility in Maple Grove, Minnesota
02/07/2018
The company, which is owned by London-based LivaNova PLC, said it will invest $750,000 in the building expansion. The new jobs will be created within three years.
As an incentive, the Minnesota Department of Employment and Economic Development is supporting the project with a $359,850 grant from the Job Creation Fund. The company will receive the funding once it has met investment and hiring commitments.
“Caisson is developing a minimally invasive implantable heart valve system that has the potential to benefit millions of patients worldwide,” said DEED Commissioner Shawntera Hardy. “The company’s investment in jobs and facilities is helping to grow a medical device cluster that is one of the cornerstones of the Minnesota economy.”
LivaNova PLC last May invested $72 million to acquire a full stake in the company. Prior to the acquisition, LivaNova owned 49 percent of Caisson. Caisson, which was founded in 2012, is developing a heart valve system to replace severely diseased or damaged heart valves that don’t close tightly enough.
Project Announcements
United Arab Emirates-Based Hotpack Plans Edison, New Jersey, Manufacturing Operations
05/12/2025
SSAB Expands Axis, Alabama, Production Operations
05/12/2025
Carnival Corporation Plans Miami, Florida, Headquarters Operations
05/12/2025
Merck Animal Health Expands De Soto, Kansas, Manufacturing Operations
05/12/2025
Oxford Technologies Plans Bay County, Florida, Manufacturing Operations
05/12/2025
PPG Plans Shelby, North Carolina, Manufacturing Operations
05/12/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024